AN2 Therapeutics Inc

GSK has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline, while separately expanding its tuberculosis research with AN2 Therapeutics. The Wave Life Sciences partnership focuses on RNA-based therapies targeting liver diseases using GalNAc-siRNA technology, giving GSK another modality in liver disease and access to Wave's SpiNA design platform without building that RNA chemistry capability internally. The AN2 Therapeutics work is supported by new funding from the Bill & Melinda Gates Foundation for boron-based drug discovery. The Wave hepatology move and the Gates-backed TB research funding sit within GSK's existing narrative of heavier R&D reinvestment and business development, though the high R&D spend and execution uncertainty still apply if these programs move slowly or fail to produce strong late-stage assets. The clearest next marker will be whether GSK or Wave disclose that one of the three remaining collaboration programs reaches formal candidate selection over the next research updates, triggering further milestone payments.

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that four abstracts supporting the development of epetraborole, a novel boron-containing oral candidate for polycythemia vera, will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, held September 9-12 in Houston. The abstracts highlight potential beneficial effects on erythropoiesis and hemoglobin-related parameters across clinical and nonclinical studies, with exposure-response relationships in nonhuman primates predicting human effects. George H. Talbot, M.D., Co-Founder and Senior Medical Advisor, noted the data strengthen understanding of exposure-response relationships supporting development. The company is a clinical-stage biopharmaceutical firm focused on boron chemistry-based small molecules.